2006 Biosimilars Vaccines 
pharmaphorum
FEBRUARY 23, 2022
Adoption of biosimilars in the US has been notoriously slow, but biosimilars manufacturers and outside observers expect this to change rapidly in the coming years. One way in which the pharmaceutical industry and regulators have reacted is by developing or facilitating the development of biosimilars. The short story so far.
Drug Channels
JUNE 27, 2021
As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02 on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
FEBRUARY 22, 2022
New sections cover: pharmacies’ administration of—and profits from—COVID-19 vaccines; smaller PBMs; PBM purchasing groups and GPOs; 340b split-billing software vendors; and shakeout and consolidation within retail pharmacy. We also present a more unified outlook for specialty drugs, including specialty generics and biosimilars.
FDA Law Blog: Biosimilars
FEBRUARY 4, 2025
In 2006, David Ridley, Henry Grabowski, and Jeff Moe proposed a voucher in an article in Health Affairs as an incentive to develop therapies for neglected infectious and parasitic diseases that affect hundreds of millions of people in the developing world.
pharmaphorum
FEBRUARY 26, 2021
In 2006, J&J acquired Pfizer Consumer Healthcare for $16.6 J&J’s size meant that it had the resources to bring to bear against COVID-19 as the pandemic ravaged the world in 2020 and 2021, and the company soon began work on its own vaccine in partnership with the US government. billion in cash.
Drug Channels
DECEMBER 1, 2020
If all goes well, 2021 will begin our return to normalcy, as vaccines roll out across the country. They are now poised to play a vital role in distributing COVID-19 vaccines and therapeutics as they become available. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. distribution channels for prescription drugs.
pharmaphorum
DECEMBER 2, 2020
One thing that highlighted this changed focus was the appointment of Kindler as CEO in 2006. In 2015 the company also paid $17 billion to acquire Hospira , a firm specialising in injectable drugs and biosimilars, at a time when copycat biologics were starting to make real waves in the market.
Expert insights. Personalized for you.
98 
Let's personalize your content